Myeloid-derived suppressor cells (MDSCs): what do we currently know about the effect they have against anti-PD-1/PD-L1 therapies?
Myeloid-derived suppressor cells (MDSCs)
PD-1 and PD-L1
immunotherapy
tumour microenvironment
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
11
2022
medline:
3
7
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
Recent advances in cancer treatment such as PD-1/PD-L1 checkpoint inhibitors have prompted multiple research studies to determine all of the factors that influence response or failure to these new treatments. One of those identified factors is myeloid-derived suppressor cells (MDSCs). These cells were identified and described for the first time in 2007 in laboratory mice and cancer patients. Previous studies showed that a greater number of MDSCs was directly related to a greater tumour volume. There are two clearly identified subpopulations: Mononuclear-type myeloid-derived suppressor cells (M-MDSCs) and polymorphonuclear (PMN-MDSCs). These cell population subtypes play a very important role, depending on the type of cancer, since they have the particularity of expressing PD-L1, which interacts with PD-1, inhibiting the expansion of cytotoxic T lymphocytes, promoting resistance to these treatments.
Identifiants
pubmed: 37396098
doi: 10.3332/ecancer.2023.1556
pii: can-17-1556
pmc: PMC10310335
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1556Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
The author is not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.
Références
Cancers (Basel). 2020 Sep 15;12(9):
pubmed: 32942545
Signal Transduct Target Ther. 2020 Jun 18;5(1):99
pubmed: 32555170
Signal Transduct Target Ther. 2021 Oct 7;6(1):362
pubmed: 34620838
Farm Hosp. 2020 Jul 01;44(4):141-148
pubmed: 32646345
Front Immunol. 2020 May 15;11:783
pubmed: 32508809
Cells. 2021 Feb 05;10(2):
pubmed: 33562495
Front Oncol. 2019 Apr 02;9:215
pubmed: 31001479
Curr Opin Immunol. 2018 Apr;51:68-75
pubmed: 29544121
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1117-1122
pubmed: 28096371
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
J Proteome Res. 2014 Feb 7;13(2):836-43
pubmed: 24295599
Signal Transduct Target Ther. 2021 Jan 8;6(1):4
pubmed: 33414378
Cancer Res. 2007 Jan 1;67(1):425; author reply 426
pubmed: 17210725
Inflammopharmacology. 2021 Dec;29(6):1613-1624
pubmed: 34613567
Oncoimmunology. 2018 Feb 20;7(4):e1413520
pubmed: 29632731
Int Immunopharmacol. 2017 Jun;47:173-181
pubmed: 28411578
Int J Mol Sci. 2022 May 23;23(10):
pubmed: 35628647
Biomark Res. 2023 Mar 29;11(1):34
pubmed: 36978204
J Proteome Res. 2017 Jan 6;16(1):238-246
pubmed: 27728760
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
Sci Transl Med. 2014 May 21;6(237):237ra67
pubmed: 24848257
Adv Exp Med Biol. 2017;1036:105-128
pubmed: 29275468